Literature DB >> 11402020

Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.

B Benaissa-Trouw1, D J Lefeber, J P Kamerling, J F Vliegenthart, K Kraaijeveld, H Snippe.   

Abstract

Di-, tri-, and tetrasaccharides, synthesized according to the chemical structure of pneumococcal polysaccharide type 3 (PS3), were coupled to the cross-reactive material (CRM(197)) of modified diphtheria toxin in different molar carbohydrate/protein ratios using the squarate coupling method. To study protective immunity, female BALB/c mice were subcutaneously immunized twice (with a 3-week interval) using the amount of conjugates corresponding to 2.5 microg of oligosaccharide per mouse. The conjugates evoked PS3 binding immunoglobulin G antibodies that lasted for at least 7 weeks after the booster. Immunogenicity was not influenced by the carbohydrate/protein ratio. All mice with PS3-specific antibodies survived the intraperitoneal challenge with Streptococcus pneumoniae type 3. Therefore, synthetic oligosaccharide-protein conjugates might have potential as vaccines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402020      PMCID: PMC98553          DOI: 10.1128/IAI.69.7.4698-4701.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  14 in total

Review 1.  Thymus-independent and thymus-dependent responses to polysaccharide antigens.

Authors:  K E Stein
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

Review 2.  Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease.

Authors:  H Jennings
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

Review 3.  Pneumococcal vaccines: history, current status, and future directions.

Authors:  J C Butler; E D Shapiro; G M Carlone
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

4.  Pneumococcal serotypes and their clinical relevance.

Authors:  M Kalin
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

5.  Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.

Authors:  L C Paoletti; D L Kasper; F Michon; J DiFabio; H J Jennings; T D Tosteson; M R Wessels
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

6.  The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.

Authors:  C A Laferrière; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Vaccine       Date:  1997-02       Impact factor: 3.641

7.  Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats.

Authors:  R Malley; A M Stack; M L Ferretti; C M Thompson; R A Saladino
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

8.  Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3.

Authors:  H Snippe; A J van Houte; J E van Dam; M J De Reuver; M Jansze; J M Willers
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

9.  Preparation of a semisynthetic vaccine to Streptococcus pneumoniae type 3.

Authors:  H Snippe; J E van Dam; A J van Houte; J M Willers; J P Kamerling; J F Vliegenthart
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

10.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

View more
  18 in total

1.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

2.  Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.

Authors:  Peng Xu; Meagan Kelly; Willie F Vann; Firdausi Qadri; Edward T Ryan; Pavol Kováč
Journal:  Chembiochem       Date:  2017-03-23       Impact factor: 3.164

3.  A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.

Authors:  Benjamin Schumann; Heung Sik Hahm; Sharavathi G Parameswarappa; Katrin Reppe; Annette Wahlbrink; Subramanian Govindan; Paulina Kaplonek; Liise-Anne Pirofski; Martin Witzenrath; Chakkumkal Anish; Claney L Pereira; Peter H Seeberger
Journal:  Sci Transl Med       Date:  2017-03-08       Impact factor: 17.956

4.  Doubly branched hexasaccharide epitope on the cell wall polysaccharide of group A streptococci recognized by human and rabbit antisera.

Authors:  Francis Michon; Samuel L Moore; John Kim; Milan S Blake; France-Isabelle Auzanneau; Blair D Johnston; Margaret A Johnson; B Mario Pinto
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

Authors:  Dodi Safari; Huberta A T Dekker; John A F Joosten; Dirk Michalik; Adriana Carvalho de Souza; Roberto Adamo; Martina Lahmann; Andreas Sundgren; Stefan Oscarson; Johannis P Kamerling; Harm Snippe
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

6.  Structures of synthetic O-antigen fragments from serotype 2a Shigella flexneri in complex with a protective monoclonal antibody.

Authors:  B Vulliez-Le Normand; F A Saul; A Phalipon; F Bélot; C Guerreiro; L A Mulard; G A Bentley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-10       Impact factor: 11.205

7.  Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups.

Authors:  Saeyoung Park; Archana R Parameswar; Alexei V Demchenko; Moon H Nahm
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

8.  T cells control the generation of nanomolar-affinity anti-glycan antibodies.

Authors:  Zinaida Polonskaya; Shenglou Deng; Anita Sarkar; Lisa Kain; Marta Comellas-Aragones; Craig S McKay; Katarzyna Kaczanowska; Marie Holt; Ryan McBride; Valle Palomo; Kevin M Self; Seth Taylor; Adriana Irimia; Sanjay R Mehta; Jennifer M Dan; Matthew Brigger; Shane Crotty; Stephen P Schoenberger; James C Paulson; Ian A Wilson; Paul B Savage; M G Finn; Luc Teyton
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

9.  Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.

Authors:  Dirk J Lefeber; Barry Benaissa-Trouw; Johannes F G Vliegenthart; Johannis P Kamerling; Wouter T M Jansen; Kees Kraaijeveld; Harm Snippe
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolates.

Authors:  Saeyoung Park; Sabina Gerber; Jean C Lee
Journal:  Infect Immun       Date:  2014-09-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.